Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti-cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistance to the first-, second-, and third-generation drugs. To explore alternatives to such whack-a-mole strategies, we simulated in patient-derived xenograft models the situation of patients receiving first-line TKIs. Monotherapies comprising approved first-line TKIs were compared to combinations with antibodies specific to EGFR and HER2. We observed uniform and strong superiority of all drug combinations over the respective monotherapies. Prolonged treatments, high TKI dose, and specificity were essential for drug–drug cooperation. Blocking pathways essential for mitosis (e.g., FOXM1), along with downregulation of resistance-conferring receptors (e.g., AXL), might underlie drug cooperation. Thus, upfront treatments using combinations of TKIs and antibodies can prevent emergence of resistance and hence might replace the widely applied sequential treatments utilizing next-generation TKIs.

Marrocco, I., Romaniello, D., Vaknin, I., Drago-Garcia, D., Oren, R., Uribe, M. L., Belugali Nataraj, N., Ghosh, S., Eilam, R., Salame, T. -., Lindzen, M., Yarden, Y., Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models, <<EMBO MOLECULAR MEDICINE>>, 2021; 13 (4): N/A-N/A. [doi:10.15252/emmm.202013144] [https://hdl.handle.net/10807/227182]

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Marrocco, Ilaria
Primo
;
2021

Abstract

Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti-cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistance to the first-, second-, and third-generation drugs. To explore alternatives to such whack-a-mole strategies, we simulated in patient-derived xenograft models the situation of patients receiving first-line TKIs. Monotherapies comprising approved first-line TKIs were compared to combinations with antibodies specific to EGFR and HER2. We observed uniform and strong superiority of all drug combinations over the respective monotherapies. Prolonged treatments, high TKI dose, and specificity were essential for drug–drug cooperation. Blocking pathways essential for mitosis (e.g., FOXM1), along with downregulation of resistance-conferring receptors (e.g., AXL), might underlie drug cooperation. Thus, upfront treatments using combinations of TKIs and antibodies can prevent emergence of resistance and hence might replace the widely applied sequential treatments utilizing next-generation TKIs.
2021
Inglese
Marrocco, I., Romaniello, D., Vaknin, I., Drago-Garcia, D., Oren, R., Uribe, M. L., Belugali Nataraj, N., Ghosh, S., Eilam, R., Salame, T. -., Lindzen, M., Yarden, Y., Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models, <<EMBO MOLECULAR MEDICINE>>, 2021; 13 (4): N/A-N/A. [doi:10.15252/emmm.202013144] [https://hdl.handle.net/10807/227182]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/227182
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 13
  • ???jsp.display-item.citation.isi??? ND
social impact